Objective
Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the disease, which includes not only molecular changes within the tumor cell itself, but also within its microenvironment. Tumor angiogenesis, tumor-stroma interactions, interactions with immune cells, with the extracellular matrix and cancer stem cell niches allow for malignant cell survival and promote metastasis, the leading cause for cancer-associated mortality. Proteoglycans (PGs) and glycosaminoglycans (GAGs) – structurally diverse carbohydrates of the extracellular matrix and cell surfaces - have emerged as novel biomarkers and molecular players both within tumor cells and their microenvironment, as they integrate signals from growth factors, chemokines and integrins, and cell-cell as well as matrix adhesion. Importantly, their expression is dysregulated in numerous tumor entities, and has been shown to modulate each of the hallmarks of cancer as defined by Hanahan and Weinberg (Cell 2011). We hypothesize that dysregulated function of PGs and GAGs simultaneously affects all molecular steps towards cancer metastasis as a general principle applicable to multiple tumor entities. Pharmacological modulation of their function thus emerges as an attractive multitargeted antitumoral approach which simultaneously acts at multiple levels of disease progression. Besides providing extensive knowledge transfer and training for researchers, the combined expertise of the GLYCANC consortium aims at performing a detailed structural analysis of PG and GAG glycans in disease using state-of-the art methodology, analysing their regulation via epigenetic mechanisms and microRNAs, and elucidating molecular mechanisms underlying aberrant PG and GAG function. GLYCANC will lead to a deeper understanding of glycan structures and glycan-dependent mechanisms promoting cancer progression, providing the basis for rational multitargeted anticancer approaches.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- natural sciencesbiological sciencesbiochemistrybiomoleculescarbohydrates
- medical and health sciencesclinical medicineoncology
- natural sciencesphysical sciencesopticsspectroscopy
Programme(s)
Coordinator
48149 Muenster
Germany
See on map
Participants (8)
51100 Reims
See on map
21100 Varese
See on map
265 04 Rio Patras
See on map
751 05 Uppsala
See on map
15341 Agia Paraskevi
See on map
48147 Muenster
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
35031 Abano Terme
See on map
1085 Budapest
See on map
Partners (4)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
21941 590 Rio De Janeiro
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
12613 Giza
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
C1425FQB Buenos Aires
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
120 750 Seoul
See on map